Denali-Sanofi Scraps Mid-stage Study for Multiple Sclerosis Drug

(Reuters) -Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary study goals.
Multiple sclerosis is a debilitating neurological condition where the immune system degrades the protective covering of nerves.
The drug candidate, oditrasertib, co-developed by Sanofi and Denali, had failed to meet the main goal another mid-stage study testing it as a treatment for amyotrophic lateral sclerosis, a fatal neurodegenerative disease.
Sanofi and Denali had entered into a partnership in 2018, in which Sanofi agreed to conduct trials to test therapies developed by Denali for neurological and inflammatory diseases.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)
 
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.